Patents by Inventor Seung Y. Chu

Seung Y. Chu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6
    Publication number: 20240132584
    Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
    Type: Application
    Filed: July 5, 2023
    Publication date: April 25, 2024
    Inventors: Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20230272114
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: December 22, 2022
    Publication date: August 31, 2023
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Heterodimeric antibodies that bind CD3 and CLDN6
    Patent number: 11739144
    Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: August 29, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 11566080
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: January 31, 2023
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6
    Publication number: 20220289839
    Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 15, 2022
    Inventors: Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
  • Heterodimeric antibodies that bind CD3 and CD38
    Patent number: 11352442
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • Bispecific antibodies that bind to CD38 and CD3
    Patent number: 10858451
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: December 8, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Y. Chu, Gregory Moore, John Desjarlais
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20200332024
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: February 5, 2020
    Publication date: October 22, 2020
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
    Publication number: 20200199251
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Application
    Filed: October 22, 2019
    Publication date: June 25, 2020
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
    Publication number: 20180305465
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Application
    Filed: November 23, 2016
    Publication date: October 25, 2018
    Inventors: Jennitte Leann Stevens, Mercedesz Balazs, Olivier Nolan-Stevaux, Gregory Moore, John Desjarlais, Matthew J. Bernett, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • Bispecific Antibodies That Bind to CD38 and CD3
    Publication number: 20180094079
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Application
    Filed: October 17, 2017
    Publication date: April 5, 2018
    Inventors: Matthew J. Bernett, Seung Y. Chu, Gregory Moore, John Desjarlais
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20170335013
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: March 16, 2017
    Publication date: November 23, 2017
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9617348
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: April 11, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Optimized anti-CD30 antibodies
    Patent number: 9574006
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: February 21, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-lu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9540451
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: January 10, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9266966
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 23, 2016
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9221916
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: December 29, 2015
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9062117
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: June 23, 2015
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20150139985
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: October 8, 2014
    Publication date: May 21, 2015
    Inventors: JOHN DESJARLAIS, SEUNG Y. CHU, HOLLY M. HORTON, MATTHEW J. BERNETT
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20150093379
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 2, 2015
    Inventors: JOHN DESJARLAIS, SEUNG Y. CHU, HOLLY M. HORTON, MATTHEW J. BERNETT